A Nature Medicine Phase 1 trial combining englumafusp alfa and glofitamab in B-cell NHL reveals how rational dose escalation...
Akeso doses first patient in AK146D1 Phase II Study for advanced NSCLC, combining dual-target ADC with ivonescimab immunotherapy.
FDA's March 2026 approval of AVLAYAH marks the first BBB-crossing biologic — but CNS trial design, PK monitoring, and...
Arletta Pharma's Lybrido for female sexual desire disorder advances with FDA backing for a single-trial Phase 3 pathway.
Ambient AI scribes reduce physician burnout—but a Lancet case reveals they systematically drop psychosocial context that drives protocol adherence...
Neurizon completes NUZ-001 ALS Trial enrollment of 250 patients in five months, with topline results expected in late Q2...
FDA clears IND for Umoja's in vivo CAR T therapy UB-VV400, targeting relapsed B cell malignancies with a single...
A Phase 1 trial pairing englumafusp alfa with glofitamab in B-cell NHL reveals a mechanistic shift reshaping how sponsors...
With enrollment complete at 48 centers across three countries, CEO Ted Ruppel and VP of Marketing Mary Dennehy explain...
RT-114 oral bioavailability exceeded subcutaneous dosing by over 150% in Phase 1a, marking a significant advance for GLP-1 delivery.
